← ANALYST RATINGS · TIPRANKS
Cytek Biosciences (CTKB): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy2 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $5.83, the highest $7.50, the lowest $5.00. The average is +11.1% from the last price of $5.25.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $5.50 → $5.00−9.1% | Hold | −4.8% | Reiterated | 09.10.26on TipRanks Oct 12 09:50 | +0.7%next day −2.1% · 5 days −1.3% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $5.50 → $6.00+9.1% | Hold | +14.3% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $5.00 → $5.50+10.0% | Hold | +4.8% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $5.50 → $6.00+9.1% | Hold | +14.3% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $5.00 → $5.50+10.0% | Hold | +4.8% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $5.50 → $6.00+9.1% | Hold | +14.3% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $5.50 → $6.00+9.1% | Hold | +14.3% | Reiterated | 23.09.26on TipRanks 06:06 | — | |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $5.50 | Hold | +4.8% | Reiterated | 06.08.26on TipRanks 07:10 | −0.3%next day +0.4% · 5 days +16.3% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $7.50 | Buy | +42.9% | Reiterated | 06.08.26on TipRanks 07:01 | −0.3%next day +0.4% · 5 days +16.3% | ↗ |
| Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% | TD Cowen | $5.00 | Hold | −4.8% | Reiterated | 05.08.26on TipRanks Aug 6 06:00 | −2.1%next day −0.3% · 5 days +14.0% | ↗ |
| Mason Carrico★★★★★★★★★★#10833 · hits 38% · avg −4.7% | Stephens | $4.75 | Buy | −9.5% | Assigned | 13.05.26on TipRanks 07:35 | −9.5%next day −9.6% · 5 days +2.6% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Cytek Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $6.00 at a price of $5.96 (+0.7%); now: $5.83 at $5.25 (+11.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.07 (from $-0.08 to $-0.06). Last quarter: $-0.09.
Sales
Next quarter’s sales estimate — $53M (from $53M to $53M). Last quarter: $48M.
Best top-analyst consensus in the sector · Healthcare
About Cytek Biosciences
- CEO: Wenbin Jiang
- Employees: 682
- 47215 Lakeview Boulevard, Fremont, CA, 94538-6407, US
- cytekbio.com
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially a
Data from the stock’s TipRanks forecast page, read 215 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗